Literature DB >> 36008692

[Tumor predisposition syndromes and nephroblastoma : Early diagnosis with imaging].

N Welter1, R Furtwängler2, G Schneider3, N Graf2, J-P Schenk4.   

Abstract

CLINICAL/METHODICAL ISSUE: The Beckwith-Wiedemann spectrum (BWSp) as well as the WT1-related syndromes, Denys-Drash syndrome (DDS) and WAGR spectrum (Wilms tumor, Aniridia, genitourinary anomalies and a range of developmental delays) are tumor predisposition syndromes (TPS) of Wilms tumor (WT). Patients with associated TPS are at higher risk of developing chronic kidney disease and bilateral and metachronous tumors as well as nephrogenic rests. STANDARD RADIOLOGICAL
METHODS: Standard imaging diagnostics for WT include renal ultrasound and magnetic resonance imaging (MRI). In the current renal tumor studies Umbrella SIOP-RTSG 2016 and Randomet 2017, thoracic computed tomography (CT) is also recommended as standard. Positron emission tomography (PET)-CT and whole-body MRI, on the other hand, are not part of routine diagnostics. METHODOLOGICAL INNOVATIONS: In recent publications, renal ultrasound is recommended every 3 months until the age of 7 years in cases of clinical suspicion or molecularly proven TPS. PERFORMANCE: Patients with TPS and regular renal ultrasounds have smaller tumor volumes and lower tumor stages at WT diagnosis than patients without such a screening. This allows a reduction of therapy intensity and facilitates the performance of nephron sparing surgery, which is prognostically relevant especially in bilateral WT. ACHIEVEMENTS: Early diagnosis of WT in the context of TPS ensures the greatest possible preservation of healthy and functional renal tissue. Standardized screening by regular renal ultrasounds should therefore be firmly established in clinical practice. PRACTICAL RECOMMENDATIONS: The initial diagnosis of TPS is clinical and requires a skilled and attentive examiner in the presence of sometimes subtle clinical manifestations, especially in the case of BWSp. Clinical diagnosis should be followed by genetic testing, which should then be followed by sonographic screening.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Differential diagnosis; Magnetic resonance imaging; Nephroblastomatosis; Screening by ultrasound; Wilms tumor

Year:  2022        PMID: 36008692     DOI: 10.1007/s00117-022-01056-w

Source DB:  PubMed          Journal:  Radiologie (Heidelb)        ISSN: 2731-7048


  43 in total

1.  High incidence of malformation syndromes in a series of 1,073 children with cancer.

Authors:  Johannes Hans M Merks; Huib N Caron; Raoul C M Hennekam
Journal:  Am J Med Genet A       Date:  2005-04-15       Impact factor: 2.802

2.  Congenital anomalies and childhood cancer in Great Britain.

Authors:  S A Narod; M M Hawkins; C M Robertson; C A Stiller
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

3.  Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1.

Authors:  Anja Lehnhardt; Claartje Karnatz; Thurid Ahlenstiel-Grunow; Kerstin Benz; Marcus R Benz; Klemens Budde; Anja K Büscher; Thomas Fehr; Markus Feldkötter; Norbert Graf; Britta Höcker; Therese Jungraithmayr; Günter Klaus; Birgit Koehler; Martin Konrad; Birgitta Kranz; Carmen R Montoya; Dominik Müller; Thomas J Neuhaus; Jun Oh; Lars Pape; Martin Pohl; Brigitte Royer-Pokora; Uwe Querfeld; Reinhard Schneppenheim; Hagen Staude; Giuseppina Spartà; Kirsten Timmermann; Frauke Wilkening; Simone Wygoda; Carsten Bergmann; Markus J Kemper
Journal:  Clin J Am Soc Nephrol       Date:  2015-03-27       Impact factor: 8.237

Review 4.  WAGR syndrome: a clinical review of 54 cases.

Authors:  Bernard V Fischbach; Kelly L Trout; Julia Lewis; Catherine A Luis; Mohammed Sika
Journal:  Pediatrics       Date:  2005-10       Impact factor: 7.124

5.  Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.

Authors:  J Pelletier; W Bruening; C E Kashtan; S M Mauer; J C Manivel; J E Striegel; D C Houghton; C Junien; R Habib; L Fouser
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

6.  Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.

Authors:  H Reinhard; O Semler; D Bürger; U Bode; M Flentje; U Göbel; P Gutjahr; I Leuschner; E Maass; F Niggli; H G Scheel-Walter; M Stöckle; J W Thüroff; J Tröger; A Weirich; D von Schweinitz; A Zoubek; N Graf
Journal:  Klin Padiatr       Date:  2004 May-Jun       Impact factor: 1.349

7.  Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients.

Authors:  H Segers; R Kersseboom; M Alders; R Pieters; A Wagner; M M van den Heuvel-Eibrink
Journal:  Eur J Cancer       Date:  2012-07-14       Impact factor: 9.162

8.  Malformations, genetic abnormalities, and Wilms tumor.

Authors:  S Dumoucel; M Gauthier-Villars; D Stoppa-Lyonnet; P Parisot; H Brisse; P Philippe-Chomette; S Sarnacki; L Boccon-Gibod; S Rossignol; C Baumann; I Aerts; F Bourdeaut; F Doz; D Orbach; H Pacquement; J Michon; G Schleiermacher
Journal:  Pediatr Blood Cancer       Date:  2013-08-23       Impact factor: 3.167

Review 9.  Expert consensus document: Clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement.

Authors:  Frédéric Brioude; Jennifer M Kalish; Alessandro Mussa; Alison C Foster; Jet Bliek; Giovanni Battista Ferrero; Susanne E Boonen; Trevor Cole; Robert Baker; Monica Bertoletti; Guido Cocchi; Carole Coze; Maurizio De Pellegrin; Khalid Hussain; Abdulla Ibrahim; Mark D Kilby; Malgorzata Krajewska-Walasek; Christian P Kratz; Edmund J Ladusans; Pablo Lapunzina; Yves Le Bouc; Saskia M Maas; Fiona Macdonald; Katrin Õunap; Licia Peruzzi; Sylvie Rossignol; Silvia Russo; Caroleen Shipster; Agata Skórka; Katrina Tatton-Brown; Jair Tenorio; Chiara Tortora; Karen Grønskov; Irène Netchine; Raoul C Hennekam; Dirk Prawitt; Zeynep Tümer; Thomas Eggermann; Deborah J G Mackay; Andrea Riccio; Eamonn R Maher
Journal:  Nat Rev Endocrinol       Date:  2018-01-29       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.